GreenLight Clinical (GLC) is a privately held Contract Research Organisation headquartered in Sydney, Australia, with offices in the United States and a presence across the Asia-Pacific region. The company is physician-led and holds ISO 9001 Management System Accreditation, with all operations conducted in strict accordance with ICH Good Clinical Practice (GCP) guidelines and both local and international regulatory requirements. The website was established in 2024, indicating GLC is a relatively recently formalised commercial entity, though its leadership team brings prior industry experience across pharmaceutical and CRO settings.

GLC’s primary client base is small and mid-sized biotech companies, for whom it positions itself as an agile, solutions-focused partner capable of accommodating diverse study needs and timelines. Named clients include Long Bridge Medical, Biosergen, and Surface Ophthalmics — all early-to-mid-stage biotech organisations operating in ophthalmic and rare disease indications, consistent with GLC’s stated therapeutic specialisation.

A core commercial proposition of GLC is its ability to leverage Australia’s favourable clinical trial environment, which offers a 43.5% R&D tax incentive for eligible overseas sponsors, fast-track regulatory processes for qualifying trials via the TGA, access to high-quality healthcare infrastructure, a diverse multicultural patient population, and cost competitiveness relative to US and European trial execution.

Key Products and Services

Clinical Operations

• Study feasibility and site selection
• Study start-up and site activation
• Project management — timeline, budget, and milestone accountability across the full trial lifecycle
• Clinical monitoring — on-site and remote monitoring to ICH-GCP standards

Site Management

• Investigator site contracting, training, and ongoing relationship management
• Site performance oversight and query resolution
• Patient enrolment support and retention management

Data Management

• eCRF design, database development, and data review
• Medical coding (MedDRA and WHO Drug)
• Database lock and data transfer to sponsor or regulatory submission package

Biostatistics

• Statistical analysis plan development, sample size calculations, and randomisation design
• Interim and final statistical analyses and reporting

Medical Writing

• Clinical study protocols, clinical study reports (CSRs), investigator brochures, informed consent forms, and regulatory submission documents

Regulatory Affairs

• Regulatory strategy and submission support for TGA (Australia), FDA, and other relevant authorities
• CTA and IND preparation; ethics committee and IRB submission management across covered markets

Pharmacovigilance and Medical Monitoring

• Adverse event and SAE processing, medical monitoring, and safety reporting
• DSUR/PSUR preparation and submission support

Quality Assurance

• GCP compliance, audit readiness, and quality management system oversight
• Regular internal audits and continuous performance evaluation

Therapeutic Areas

Ophthalmology (primary focus, with named clients including Surface Ophthalmics and Long Bridge Medical), Oncology, Rare Disease, and Cell and Gene Therapy.

GreenLight Clinical occupies the boutique, therapeutic-specialist segment of the Australian CRO market, targeting small and mid-sized biotech sponsors whose clinical programmes require a responsive, senior-engaged partner rather than the large CRO infrastructure calibrated for multinational pharmaceutical companies. Its physician-led model and stated specialisation in ophthalmology, oncology, rare disease, and cell and gene therapy provide a degree of scientific focus that differentiates it from generalist Australian CROs. The Australian clinical trial environment — particularly the R&D tax incentive and TGA regulatory framework — is a meaningful commercial asset for overseas sponsors evaluating early-phase or proof-of-concept study locations, and GLC’s positioning around these benefits is well suited to its target client profile of capital-constrained early-stage biotechs seeking to maximise development efficiency. As a relatively recently formalised CRO with a growing but still limited public track record, its scale and breadth of operational experience remain developing compared to more established regional CROs.